Log in to search using one of your social media accounts:

 

Detection of the Murmur of Advanced Aortic Stenosis Detection of the Murmur of Advanced Aortic Stenosis
How proficient are physicians at detecting aortic stenosis via ascultation? What role does patient characteristics and clinical context play in their success?Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Rapid Deployment Valve for Aortic Stenosis Ups Stroke Risk
FRIDAY, April 13, 2018 -- For patients with aortic valve stenosis, treatment with a rapid deployment valve (RDV) is associated with increased rates of new-onset pacemaker implantation and disabling stroke, compared with conventional biological... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2018 Category: Pharmaceuticals Source Type: news

JenaValve Is a Growing Force to be Reckoned with in TAVR
It would be a big mistake to leave JenaValve out of the transcatheter aortic valve replacement (TAVR) market conversation. The Munich, Germany-based company has been biding its time and reaching milestones, in the hopes of obtaining some serious market share in the TAVR space. The small company's latest achievement is successfull enrollment in the CE mark study of the next generation of JenaValve Pericardial TAVR system. “It’s very tricky to develop a TAVR system because it can take several iterations before you can get it right,” Victoria Carr-Brendel, JenaValve CEO, told MD+DI. “We think we ...
Source: MDDI - April 11, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Implants Source Type: news

NOTION: 5-Year TAVR vs SAVR Outcomes Similar in Low-Risk Patients NOTION: 5-Year TAVR vs SAVR Outcomes Similar in Low-Risk Patients
All-cause mortality, MI, and stroke were similar in low-risk patients with severe aortic stenosis who had transcatheter aortic valve replacement and those who had surgery, but 42% of TAVR patients needed pacemakers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 9, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Edwards Eyes Delay for its Sapien 3 Ultra TAVR
Edwards Lifesciences said it is delaying the launch of the Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) System in Europe until later this year. The Irvine, CA-based company said it would refocus on commercialization efforts after it submits data from the 30-patient, single-arm study of the device treating patients at intermediate risk from surgical valve replacement. The study data would help supplement the company’s bid to gain CE mark for the technology. Edwards said the updated timing for the European launch of the Sapien 3 Ultra doesn’t change the company’s sales guidance for 2018...
Source: MDDI - March 22, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

Colibri Course Corrects to be Relevant in TAVR
Colibri Heart Valve LLC has started a feasibility study of its second-generation transcatheter aortic valve replacement system that will treat patients with severe aortic stenosis. The Broomfield, CO-based company said it has treated two patients in the study with its redesigned valve. “We spent the last three years modifying our product because the market has changed so drastically from 2012, in both patient indications and also bicuspid valves,” Joseph Horn, president and CEO of Colibri Heart Valve, told MD+DI. “We decided that the product we had was probably not going to be robust enough to satisfy the...
Source: MDDI - March 19, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Implants Source Type: news

TAVR Reasonable for Low-Flow, Low-Gradient Aortic Stenosis (CME/CE)
(MedPage Today) -- Low 30-day mortality observed in high-risk group (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - March 19, 2018 Category: Surgery Source Type: news

Medtronic and Edwards Duel in TAVR Space
A pair of studies support the long-term use of Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system. The Dublin-based company unveiled results from both the Nordic Aortic Valve Intervention Trial (NOTION) and the CoreValve U.S. Pivotal Extreme Risk Study at the American College of Cardiology 67th Annual Scientific Session (ACC) this past weekend. NOTION is a physician-initiated trial that studied an all-comers population of 280 patients at least 70 years old. Patients in the trial were randomized to either Surgical Aortic Valve Replacement (SAVR) or TAVR procedures. Join us at the BIOM...
Source: MDDI - March 13, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Edwards Adds Bold New Chapter to TAVR Story
Edwards Lifesciences just might have leaped-frogged over some of its competitors in the burgeoning  TAVR market. The undisputed TAVR pioneer has received CE mark for its Centera valve to treat severe, symptomatic aortic stenosis patients at high risk of open-heart surgery. The Edwards Centera valve is repositionable and retrievable and can be delivered through a low-profile, 14-French, motorized delivery system. The company said the device is packaged with the valve fully pre-attached to the delivery system, which helps with simple and rapid device preparation. Network with your colleagues in medtech at ADM&...
Source: MDDI - February 15, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Medical Device Business Source Type: news

Edwards Lifesciences wins CE Mark for Centera TAVR
Edwards Lifesciences (NYSE:EW) said today it won CE Mark approval in the European Union for its self-expanding transcatheter Centera aortic heart valve, with indications for treating symptomatic aortic stenosis patients at high risk of open-heart surgery. The Centera valve is designed to be repositionable and retrievable, and is delivered through the use of a 14 French motorized delivery system in which the valve is pre-attached to the mechanism for quick preparation, the Irvine, Calif.-based company said. “With the Edwards Centera valve, European clinicians and their patients may now benefit from a self-ex...
Source: Mass Device - February 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Regulatory/Compliance Replacement Heart Valves Edwards Lifesciences Source Type: news

The Future of TAVI The Future of TAVI
While TAVI has emerged as the established therapy for patients with severe, symptomatic aortic stenosis, there are still challenges that remain, and improvements that can be made.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Cardiac Amyloid Buildup Not Uncommon In TAVR Patients
(MedPage Today) -- Study opens question of interaction between aortic stenosis, amyloid (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 22, 2018 Category: Cardiology Source Type: news

Ashfield are shortlisted for a PM Award
Ashfield Digital & Creative, alongside our colleagues at Watermeadow Medical and our clients at Edwards Lifesciences, are thrilled to announce that we have been shortlisted for a PM Society Award in the Primary Care Campaign category for ‘Listen to the Heart’. A campaign focused on the lifesaving opportunity available to GPs through the early identification of aortic stenosis. Speaking about the collaboration, which led to this campaign, Ashfield Digital & Creative Senior Vice-President Andrew Binns said, “This entry demonstrates the impact that can be achieved when strategic insights and cre...
Source: Ashfield Healthcare News - January 18, 2018 Category: Pharmaceuticals Authors: Daniel Goodwin Tags: Ashfield Source Type: news

Edwards Lifesciences recalls Certitude delivery device for Sapien 3 valve
Edwards Lifesciences (NYSE:EW) is recalling the Certitude delivery device used with its Sapien 3 replacement heart valve on the risk that a molding defect could embolize, the FDA said today. The Sapien 3 is a transcatheter aortic valve replacement designed to treat aortic stenosis. During implantation the valve is crimped to Certitude’s balloon before either transapical or transaortic insertion into the body. The recall, of some lots made between Nov. 22, 2016, and July 10 of last year, is due to a molding overflow defect in the button valve within Certitude’s loader, according to the federal safety watchd...
Source: Mass Device - January 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Recalls Replacement Heart Valves Edwards Lifesciences Source Type: news

3 Reasons TAVR Will Continue to Prosper
The transcatheter aortic valve replacement (TAVR) market has already seen rapid growth, and today represents a $3 billion market globally. But the leading TAVR companies say the current technology and approved indications barely scratches the surface in terms of the true growth potential of the space. Michael Mussallem, CEO of Edwards Lifesciences, told J.P. Morgan Healthcare Conference attendees on Monday that the global TAVR market is expected to exceed $5 billion by 2021, and that number does not include certain indications that are currently being explored, like treatment for patients with asymptomatic aortic...
Source: MDDI - January 9, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Impaired Survival With LVEF < 60 Percent in Aortic Stenosis
Poorer outcomes seen for LVEF (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 5, 2018 Category: Respiratory Medicine Tags: Cardiology, Nursing, Pathology, Pulmonology, Critical Care, Journal, Source Type: news

' Normal' LVEF: Misnomer in Aortic Stenosis?
(MedPage Today) -- Study shows survival in severe aortic stenosis impaired with LVEF (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 27, 2017 Category: Cardiology Source Type: news

Can Boston Scientific Bounce Back from Lotus Setback?
Boston Scientific shares took a beating Tuesday after the company abruptly backed out of a scheduled appearance at the annual Piper Jaffray healthcare conference in New York. As investors seemed to fear, the sudden change of plans foreshadowed another Lotus setback. The company's stock (NYSE: BSX) dropped 7.5% by market close on Tuesday, slashing Boston Scientific's market cap by about $2.9 billion. About three hours after the close, the company said it had pushed back its previously-reported timelines for re-introducing the Lotus Edge aortic valve system in Europe, and the filing of a final pre-market approval (PMA) modul...
Source: MDDI - November 29, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Medical Device Business Cardiovascular Source Type: news

Boston Scientific takes a $3B hit on latest Lotus valve delay
Boston Scientific (NYSE:BSX) saw its market capitalization lose $3 billion after yesterday revealing another delay for its Lotus replacement heart valve. The Marlborough, Mass.-based company, which recalled the Lotus transcatheter aortic heart valve in February over issues with its locking mechanism, said it no longer expects the ensuing manufacturing and design specification changes to get the valve back on the market in Europe or allow the final filing in its pre-market approval bid with the FDA by January 2018. “We continue to see value in the unique benefits of the LOTUS Valve platform in treating patients w...
Source: Mass Device - November 29, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Replacement Heart Valves Wall Street Beat Boston Scientific Source Type: news

Afternoon open heart surgery 'leads to fewer complications'
Conclusion This study found evidence of an effect that's worth investigating further to see if there are real differences in heart muscle function and risk of complications from heart surgery at different times of the day. However, there were some limitations: It took place at a single hospital, with a relatively small number of people undergoing operations. The laboratory study found differences in gene activity that suggested the body clock may play a role in making the heart better able to tolerate loss of oxygen and subsequent re-oxygenation. However, there may be other explanations for these differences. For example, ...
Source: NHS News Feed - October 27, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

RAS Blockade After TAVI Tied to Better Outcomes (CME/CE)
(MedPage Today) -- Patients with severe aortic stenosis see reduced all-cause mortality (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - October 26, 2017 Category: Urology & Nephrology Source Type: news

All-Time High for Obesity; Aortic Stenosis AUC; Prognosticating Cardiac Arrest
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - October 20, 2017 Category: Pediatrics Source Type: news

TAVR Looms Large in First AUC Document for Severe Aortic Stenosis TAVR Looms Large in First AUC Document for Severe Aortic Stenosis
There are more treatment options than ever before, but guidelines only go so far when the patient is 90-something, frail, and with multiple chronic disorders, for example.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 20, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Appropriate Use Criteria Developed for Aortic Stenosis Tx
SAVR or TAVR appropriate for most patients with symptomatic AS at intermediate or high surgical risk (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 18, 2017 Category: Respiratory Medicine Tags: Cardiology, Nursing, Pulmonology, Surgery, Journal, Source Type: news

First Appropriate Use Criteria for Severe Aortic Stenosis Published (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American College of Cardiology, the American Heart Association, and nine other medical groups have issued the first-ever appropriate use criteria for treating severe aortic stenosis.The … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 18, 2017 Category: Primary Care Source Type: news

First Appropriate Use Criteria Issued for Severe Aortic Stenosis
(MedPage Today) -- Multi-society guide OKs intervention for most symptomatic cases (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 17, 2017 Category: Primary Care Source Type: news

Shockwave Medical raises $35m for Lithoplasty devices
Shockwave Medical said today that it raised another $35 million for the Lithoplasty devices it’s commercializing to treat blocked arteries. Fremont, Calif.-based Shockwave said it plans to use the new funding, which was led by new backer Fidelity Management & Research, to commercialize its existing devices for treating coronary and peripheral vessels in the U.S. and Europe and to evaluate the Lithoplasty tech in treating aortic valve stenosis. T. Rowe Price Assoc. also participated in the financing, which Shockwave said was an extension of its $45 million Series C round. The Lithoplasty devices are...
Source: Mass Device - October 10, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Funding Roundup Ultrasound Wall Street Beat peripheral Shockwave Medical Source Type: news

Medtronic launches post-market study of CoreValve Evolut Pro heart valve
Medtronic (NYSE:MDT) said today it launched a post-market clinical study of its CoreValve Evolut Pro valve, looking to evaluate performance out to 5 years for the self-expanding transcather aortic valve implantation system. The multi-center, prospective single-arm study aims to enroll 600 patients across 35 European sites to evaluate the safety of the CoreValve Evolut Pro, including all-cause mortality and all stroke at 30 days and clinical performance including valve hemodynamics and paravalvular regurgitation. “We look forward to replicating the excellent clinical outcomes demonstrated by the Evolut Pro valve ...
Source: Mass Device - September 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Medtronic Source Type: news

Medical societies expand collaboration on cardiac registry
The American Society of Nuclear Cardiology (ASNC) and the American Society...Read more on AuntMinnie.comRelated Reading: ASNC, SNMMI advise on cardiac sarcoidosis ASNC releases guidance on MPI in women ASE: Echo protocol finds kids' heart abnormalities Echo groups release guidance on aortic stenosis Echo groups release new stress echo guidelines (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 19, 2017 Category: Radiology Source Type: news

Regular Evaluation Improves Survival in Asymptomatic Severe AS Regular Evaluation Improves Survival in Asymptomatic Severe AS
Patients with asymptomatic severe aortic stenosis followed according to guideline recommendations were more likely to undergo early valve replacement and had improved survival and reduced hospitalization.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 18, 2017 Category: Radiology Tags: Cardiology News Source Type: news

New educational resource to help GPs detect aortic stenosis early
A new interactive educational resource for GPs has been launched to support the early detection of aortic stenosis. (Source: GP Online News)
Source: GP Online News - September 14, 2017 Category: Primary Care Tags: 15.1 Cardiovascular Problems Source Type: news

Do You Listen to Heart Sounds? This May be Another Reason Why You Should.
I’m not sure about you, but when I went to school to become a paramedic (and a nurse for that matter), one thing I never really understood was heart sounds, or heart tones, depending on who taught you. My attempt at learning resorted to scouring textbooks, journals, online editorials, watching clips on YouTube and listening… lots of listening to sound bites from CDs. You know the ones, they come free when you buy a new stethoscope. Instead of turning to digital media, I should’ve been listening to the hearts of my patients. Hindsight is 20/20, especially in this case. All my self-guided education yielded...
Source: JEMS Patient Care - September 12, 2017 Category: Emergency Medicine Authors: Bruce Hoffman, MSN,BSN-RN, NR-P, CFRN Tags: Patient Care Cardiac & Resuscitation Source Type: news

Tall VTE Risk; Frequent Aortic Stenosis Checks;'Sweet Spot' for LVAD Volume
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 8, 2017 Category: Cardiology Source Type: news

Close Watch on Aortic Stenosis May Improve Outcomes
(MedPage Today) -- Single-center study supports guideline-based serial evaluations for asymptomatic patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 7, 2017 Category: Cardiology Source Type: news

Serial Echos Valuable in Patients with Asymptomatic Severe Aortic Stenosis (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM Patients with asymptomatic severe aortic stenosis who don't get regular evaluations are at increased risk for death and heart failure, according to a retrospective study in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 7, 2017 Category: Primary Care Source Type: news

Not adhering to recommended exams for severe narrowing of the aortic valve associated with increased heart failure
(The JAMA Network Journals) Patients with asymptomatic severe aortic stenosis who did not follow recommended guidelines for regular exams had poorer survival and were more likely to be hospitalized for heart failure, according to a study published by JAMA Cardiology. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 6, 2017 Category: International Medicine & Public Health Source Type: news

Intervention for Aortic Stenosis: Frailty Matters Intervention for Aortic Stenosis: Frailty Matters
The FRAILTY-AVR study evaluated different frailty scales in predicting poor outcomes following TAVR and SAVR. What did we learn and how will it influence clinical practice?Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Nonagenarians'Good Candidates' for TAVI Surgery Nonagenarians'Good Candidates' for TAVI Surgery
Severe aortic-stenosis patients aged 90 years or older can be candidates for transcatheter aortic-valve implantation, with similar outcomes to those in younger patients, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Cardiopulmonary Exercise Testing Prognostic in Aortic Stenosis
Conservative strategy results in good prognosis if CPET does not indicate hemodynamic compromise (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 25, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Pulmonology, Geriatrics, Journal, Source Type: news

Next-gen Repositionable Self-expanding Catheter Safe for Severe Aortic Stenosis Next-gen Repositionable Self-expanding Catheter Safe for Severe Aortic Stenosis
The self-expanding, repositionable Evolut R transcatheter heart valve (THV) from Medtronic appears safe and effective for treating older patients with severe aortic stenosis, according to a company-funded observational study.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2017 Category: Consumer Health News Tags: News Source Type: news

Medtronic wins FDA nod, CE Mark for Avalus aortic valve
Medtronic (NYSE:MDT) said today it won CE Mark approval in the European Union and FDA approval in the US for its Avalus pericardial aortic surgical valve designed to treat aortic valve disease. The Avalus is the Fridley, Minn.-based company’s next-gen pericardial surgical aortic valve, and features a supra-annular design to improve hemodynamic performance and limit central regurgitation. The valve also features interior-mounted leaflet and frame design for improved durability and a low-profile design with a streamlined valve holder and single, one-cut release for easier implantations, Medtronic said. “Medt...
Source: Mass Device - August 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves Medtronic Source Type: news

Medtronic touts reduced costs, rehospitalizations in cryoballoon vs RF AF ablation trial analysis
Medtronic (NYSE:MDT) today released data from a health economic analysis from the Fire And Ice trial comparing its Arctic Front cryoballoon catheter to its ThermoCool radiofrequency ablation cath, touting that cryoballoon treatment could reduce costs and rehospitalizations when used to treat paroxysmal atrial fibrillation. Economic analysis results from the trial were published today in the Journal of the American Heart Association. Researchers analyzed data from the 769-patient trial, which Medtronic claims is the largest to compare cryoballoon ablation to point-by-point RF ablation for treating paroxysmal AF, o...
Source: Mass Device - August 1, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Medtronic Source Type: news

Medtronic wins CE Mark for CoreValve Evolut Pro
Medtronic (NYSE:MDT) said today it won CE Mark approval in the European Union for its CoreValve Evolut Pro transcatheter aortic heart valve, indicated for the treatment of severe aortic stenosis for symptomatic patients at intermediate, high or extreme risk for open heart surgery The CoreValve Evolut Pro features an outer wrap to add surface area contact between the valve and the native aortic annulus to increase valve sealing performance, Fridley, Minn.-based Medtronic said. “We are excited to introduce the next evolution of our Evolut TAVI platform to provide physicians in Europe with a comprehensive portfolio...
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Regulatory/Compliance Replacement Heart Valves Medtronic Source Type: news

Experience Journal: A bereaved mother ’s lessons from the heart
Jessica Lindberg’s son Ethan was a brave heart warrior whose journey at Boston Children’s Hospital began before he was even born. At 20 weeks, they learned he had aortic stenosis and evolving hypoplastic left heart syndrome (HLHS). At 22 weeks Ethan was the 30th baby to have an in-utero procedure to open his aortic valve and relieve pressure in the left side of his heart. By the time Ethan was 2, he’d had four open-heart surgeries. He was also having feeding problems, developmental delays, and was struggling with executive functioning and spatial tasks. Like many other parents of children with congen...
Source: Thrive, Children's Hospital Boston - July 27, 2017 Category: Pediatrics Authors: Ellen Greenlaw Tags: Diseases & Conditions Our Patients’ Stories Cardiac Neurodevelopmental Program congenital heart defect Dr. Janice Ware Experience Journal Heart Center hypoplastic left heart syndrome Source Type: news

3D printing helps evaluate leaks after TAVR procedures
3D-printed phantoms of aortic root anatomy offer a noninvasive way to assess...Read more on AuntMinnie.comRelated Reading: Echo groups release guidance on aortic stenosis ACC: CT detects blood clots that reduce valve motion CT better than echo for aortic annulus before TAVR Study finds differences in CCTA plaque measurements Cutting-edge techniques transform practice of cardiac CT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 26, 2017 Category: Radiology Source Type: news

Stress Echo Value Questioned for Asymptomatic Aortic Stenosis
Neither increase in mean pressure gradient, systolic pulmonary artery pressure predicted outcome (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 26, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Nursing, Pulmonology, Radiology, Journal, Source Type: news

Morristown Medical Center Randomizes First Patient in World to New...
Morristown Medical Center Randomizes First Patient in World to New Study to Evaluate Treatment for Asymptomatic Severe Aortic Stenosis; Trial may change treatment paradigm, save heart muscle(PRWeb July 13, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14507855.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 13, 2017 Category: Pharmaceuticals Source Type: news

Study: TAVR, surgical AVR results similar at 2 years in intermediate risk patients
Transcatheter and surgical aortic valve procedures were shown to have similar outcomes at 2 years in severe aortic stenosis patients deemed to be at intermediate surgical risk, according to a recently published study. Data came from a 2-year follow up with patients in the Partner 2 trial, which aimed to explore the difference between the 2 procedures in intermediate risk patients. A total of 2,032 patients were examined in the trial, which was randomly divided into 2 cohorts, with the 1st receiving Edwards Lifesciences‘(NYSE:EW) Sapien XT and the 2nd receiving a surgical AVR procedure. At 2 years, both disease-s...
Source: Mass Device - July 12, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Edwards Lifesciences Source Type: news

FDA Expands CoreValve TAVR Indication to Intermediate-Risk Patients FDA Expands CoreValve TAVR Indication to Intermediate-Risk Patients
The expanded indication to include treatment of patients with severe aortic stenosis at intermediate risk for surgery is based on the pivotal SURTAVI data reported this March.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

FDA Gives Approval to Medtronic's CoreValve for Use in Patients at Intermediate Risk for Surgical Valve Replacement
Based on results from the landmark SURTAVI Clinical Trial, presented at the American College of Cardiology Annual Meeting in March, and published in the New England Journal of Medicine, the FDA has approved the CoreValve TAVR self-expanding platform for use in patients with severe and symptomatic aortic stenosis who are at "intermediate" risk for surgical valve replacement, defined as mortality>= 3% at 30 days. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 10, 2017 Category: Cardiology Source Type: news